Jenkins, P. | Search bioRxiv

bioRxiv2025

Intrinsic differences in hamster and mouse macrophage biology correlate with susceptibility to L. donovani infection

The basis for differential susceptibility to Leishmania (L.) donovani infection observed in individuals remains poorly understood. Here we address this important open question comparing bone marrow-derived macrophages from susceptible hamsters (hamBMDMs) and resistant mice (mBMDMs) to identify intrinsic cellular features that may contribute to host-specific outcomes. We first optimized and validated an experimental protocol for generating hamBMDMs, which closely resemble classical mouse BMDMs in terms of morphology, marker gene expression and phagocytic activity. Comparative transcriptomic analysis uncovered rodent-specific, intrinsic differences in the expression of metabolic and immune-related pathways known to influence susceptibility to intracellular Leishmania infection. In vitro infection assays confirmed the microbicidal capacity of hamBMDMs, while also revealing their increased permissiveness to Leishmania proliferation. In conclusion, the combined use of murine and hamster macrophage systems provides a powerful platform to dissect the molecular mechanisms underlying L. donovani survival and host resistance. Our improved protocol allows for the generation of large quantities of functionally validated hamster macrophages, enabling systems-level investigations in this important rodent model that more accurately reflects human infection dynamics than mice. This addresses a major bottleneck in experimental infections with L. donovani, but also other clinically relevant pathogens, such as Mycobacterium spp. and SARS-CoV-2, for which hamsters have been used to model human infection.

pathology↗

bioRxiv2022

A new concept in antiviral drug design

Contemporary antiviral development, whether by rational drug design or forward pharmacology, primarily strives to produce lock and key inhibitors. While the technology to identify druggable targets and create compounds to bind them has improved dramatically over the last century it has always been constrained by the finite availability of suitable binding sites that antiviral compounds can occupy. Here we present a new approach to drug design that utilizes compounds devised to alter the microenvironment of the virion surface making it incompatible with virus entry and illustrate this strategy with inhibitors of influenza virus. We show that compounds that produce a proton-rich mantle above the virion surface induce a conformational change in the viral hemagglutinin (HA) rendering the virus unable to interact with cellular receptors and gain entry to the cell. The compounds show exceptional antiviral activity both in vitro and in vivo and protect against influenza illness in mice and ferrets after a single dose, either therapeutically or prophylactically. The work presented here lays the foundation for a brand-new category of inhibitors that could be engineered to counter many different viruses and potentially other pathogens.

microbiology↗